Glaxo Grp Ltd Company Profile

What is the competitive landscape for GLAXO GRP LTD

GLAXO GRP LTD has eight approved drugs.

There are five US patents protecting GLAXO GRP LTD drugs.

There are one hundred and thirty-nine patent family members on GLAXO GRP LTD drugs in thirty-one countries and ten supplementary protection certificates in five countries.

Summary for Glaxo Grp Ltd

International Patents:	139
US Patents:	5
Tradenames:	13
Ingredients:	4
NDAs:	8

Drugs and US Patents for Glaxo Grp Ltd

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-003	May 12, 2023		RX	Yes	Yes
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-001	May 10, 2013		RX	Yes	Yes	8,534,281*PED				Y
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-002	Apr 30, 2015		RX	Yes	Yes	8,746,242*PED				Y
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-002	Apr 30, 2015		RX	Yes	Yes	11,116,721*PED				Y
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-003	May 12, 2023		RX	Yes	Yes	8,511,304*PED				Y
Glaxo Grp Ltd	ADVAIR DISKUS 250/50	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	021077-002	Aug 24, 2000	AB	RX	Yes	Yes

Expired US Patents for Glaxo Grp Ltd

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxo Grp Ltd	ADVAIR HFA	fluticasone propionate; salmeterol xinafoate	AEROSOL, METERED;INHALATION	021254-003	Jun 8, 2006	9,861,771
Glaxo Grp Ltd	ADVAIR HFA	fluticasone propionate; salmeterol xinafoate	AEROSOL, METERED;INHALATION	021254-003	Jun 8, 2006	RE40045
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-001	May 10, 2013	6,537,983
Glaxo Grp Ltd	ADVAIR HFA	fluticasone propionate; salmeterol xinafoate	AEROSOL, METERED;INHALATION	021254-001	Jun 8, 2006	9,861,771
Glaxo Grp Ltd	ADVAIR HFA	fluticasone propionate; salmeterol xinafoate	AEROSOL, METERED;INHALATION	021254-003	Jun 8, 2006	5,270,305
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-002	Apr 30, 2015	RE44874

Paragraph IV (Patent) Challenges for GLAXO GRP LTD drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	150 mg		2007-10-30

International Patents for Glaxo Grp Ltd Drugs

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2004001664
Croatia	P20241000
Brazil	0306799
Israel	188930
Cyprus	1108995
China	101336118

Supplementary Protection Certificates for Glaxo Grp Ltd Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2506844	18C1022	France		PRODUCT NAME: COMBINAISON COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (EN PARTICULIER LE BROMURE D'UMECLIDINIUM), DU VILANTEROL OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (EN PARTICULIER LE TRIFENATATE DE VILANTEROL), ET DU FUROATE DE FLUTICASONE; REGISTRATION NO/DATE: EU/1/17/1236 20171117
1519731	132013902182575	Italy		PRODUCT NAME: AZELASTINA CLORIDRATO/FLUTICASONE PROPIONATO(DYMISTA); AUTHORISATION NUMBER(S) AND DATE(S): 2011/07125-REG, 20111024;041808015/M-027/M-039/M-041/M, 20130527
1305329	SPC/GB08/026	United Kingdom		PRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080116; UK EU/1/07/434/002 20080116; UK EU/1/07/434/003 20080116
2506844	LUC00077	Luxembourg		PRODUCT NAME: PRODUIT DE COMBINAISON PHARMACEUTIQUE COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (PAR EXEMPLE LE BROMURE D'UMECLIDINIUM), LE VILANTEROL OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE (PAR EXEMPLE LE TRIFENATATE DE VILANTEROL) ET LE FUROATE DE FLUTICASONE; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117
2506844	132018000000341	Italy		PRODUCT NAME: UN PRODOTTO DI COMBINAZIONE FARMACEUTICA COMPRENDENTE UN SALE FARMACEUTICAMENTE ACCETTABILE DI UMECLIDINIO (AD ESEMPIO BROMURO DI UMECLIDINIO), VILANTEROLO O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE (AD ESEMPIO VILANTEROLO TRIFENATATO) E UN FUROATO(TRELEGY ELLIPTA - FLUTICASONE FUROATO/UMECLIDINIO/VILANTEROLO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1236, 20171117
2506844	SPC/GB18/020	United Kingdom		PRODUCT NAME: A PHARMACEUTICAL COMBINATION PRODUCT COMPRISING A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCETPABLE SALT THEREOF (E.G. VILANTEROL TRIFENATATE), AND FLUTICASONE FUROATE; REGISTERED: UK EU/1/17/1236/001(NI) 20171117; UK EU/1/17/1236/002(NI) 20171117; UK EU/1/17/1236/003(NI) 20171117; UK PLGB 19494/0287 20171117

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Glaxo Grp England
• Glaxo Grp Ltd
• Glaxosmithkline
• Glaxosmithkline Cons
• Glaxosmithkline Llc

Pharmaceutical Competitive Landscape Analysis: GLAXO GROUP LTD – Market Position, Strengths & Strategic Insights

Last updated: March 16, 2026

What is Glaxo Group Ltd’s current market position?

Glaxo Group Ltd (GlaxoSmithKline, GSK) is among the leading pharmaceutical companies globally with a market capitalization exceeding $80 billion as of 2023. The company ranks in the top five pharmaceutical firms based on revenue, which totaled approximately $34 billion in 2022. Its broad portfolio spans vaccines, specialty medicines, and consumer healthcare products.

Market share and revenue distribution

Segment	Revenue (2022)	Market Share (Global, Estimated)
Pharmaceuticals	$16.2 billion	4.5%
Vaccines	$11.4 billion	3%
Consumer Healthcare	$6.4 billion	N/A (part of broader health market)

GSK holds a significant position in respiratory (e.g., inhalers for asthma), vaccines (e.g., Shingrix, HPV), and HIV therapeutic areas. Its vaccine division is ranked second globally by revenue after Pfizer.

Key markets

Region	Revenue Share	Principal Therapeutic Focus
North America	45%	Vaccines, HIV, respiratory
Europe	25%	Respiratory, HIV, vaccines
Emerging Markets	30%	Malaria, tropical diseases, vaccines

What are GSK’s primary strengths?

1. Diversified Portfolio

GSK’s broad spectrum includes vaccines, prescription medicines, and consumer healthcare, reducing dependency on a single segment. Its vaccine products are essential in global immunization programs.

2. Established R&D Capabilities

GSK invests approximately 15% of its revenues into R&D, approximately $5 billion annually. The company has a pipeline of over 40 projects focused on respiratory diseases, HIV, oncology, and immunology.

3. Strategic Collaborations

Partnerships with biotech firms, governments, and international health agencies enhance GSK's research and market reach. Notable collaborations include alliances with CureVac for mRNA vaccines and development agreements with multiple biotech startups.

4. Geographic Penetration

Strong presence in North America and Europe with expanding operations in Asia and Africa. Its immunization programs under GSK’s vaccines division secure a foothold in emerging markets.

5. Patent Portfolio and Market Exclusivity

Holding over 25,000 patents globally, GSK maintains market exclusivity for key products, including vaccines like Shingrix, which generated over $4 billion in revenues in 2022.

What are the strategic challenges faced by GSK?

1. Patent Expirations

Major products like Advair/Seretide have faced patent cliffs, leading to revenue declines. The expiration of these patents reduces market exclusivity, opening opportunities for generics.

2. Competition in Core Segments

Pfizer, Moderna, and Merck are fierce competitors in vaccines and HIV. For respiratory therapies, Teva and Mylan offer generic versions that erode GSK’s market share.

3. R&D Risks

Despite high investment levels, the conversion rate of pipeline candidates to market is low, with many drugs failing clinical trials or not receiving approval.

4. Regulatory and Pricing Pressures

Global pricing regulation, especially in Europe and North America, pressures profit margins. GSK must navigate complex regulatory environments to sustain profitability.

5. Strategic Divestments

Recent strategic decisions involve divesting non-core units, such as the sale of Horlicks and other consumer health brands, to bolster focus but also indicating market pressures.

What strategic initiatives is GSK pursuing?

1. Focused R&D

GSK emphasizes immunology, oncology, and gene therapy, aiming for innovative products in these high-growth areas. It launched over 10 new drugs globally between 2021-2023.

2. Portfolio Optimization

The company is divesting non-core assets to streamline operations, including the sale of its consumer healthcare joint ventures. This shifts resources towards vaccines and specialty medicines.

3. Digital and Technological Integration

GSK invests in artificial intelligence, data analytics, and digital clinical trials to accelerate drug discovery and enhance R&D efficiency.

4. Market Expansion

Strengthening presence in Asia and Africa by partnering with local governments and healthcare providers. The launch of lower-cost vaccines and medicines aligns with market needs.

5. Strategic Collaborations

Forming alliances with biotech firms for innovative therapies, as exemplified by the recent partnership with CureVac for mRNA COVID-19 vaccines.

How does GSK compare to key industry competitors?

Company	Revenue (2022)	Core Focus Areas	R&D Investment (% of sales)	Market Cap (2023)	Notable Strategic Moves
Pfizer	$100 billion	Vaccines, Oncology, Cardio	15%	$210 billion	Acquisitions (Array BioPharma, BioNTech)
Moderna	$18.5 billion	mRNA vaccines, Oncology	25%	$40 billion	mRNA platform expansion
Merck & Co.	$59 billion	Oncology, Vaccines, Infectious Disease	13%	$225 billion	Growth in oncology pipeline, vaccines
Johnson & Johnson	$94 billion	Consumer, Medical Devices, Pharmaceuticals	16%	$430 billion	Portfolio realignment, vaccine development

GSK's positions in vaccines and HIV therapy differentiate it from peers who focus more on oncology and general pharmaceuticals. Its vaccine revenue stabilizes despite patent expirations in other segments.

Key Takeaways

• GSK has a diversified portfolio with strengths in vaccines, HIV, and respiratory products. Its market position is strong in immunization programs globally.
• Patents and product lifecycle management pose risks, though strategic divestments and pipeline investments mitigate these.
• Competition remains intense in core therapies from Pfizer, Moderna, and Merck. GSK’s focus on innovation and emerging markets attempts to offset patent cliffs.
• Heavy R&D investments aim for breakthrough therapies, especially in immunology and gene therapy.
• Future growth hinges on new product approvals, geographic expansion, and strategic alliances.

FAQs

1. What are GSK’s most profitable products?
Shingrix (herpes zoster vaccine), HIV medicines like Tivicay, and respiratory inhalers remain top revenue contributors.

2. How vulnerable is GSK to patent expirations?
Patents for key drugs expire over the next five years, risking revenue decline. Strategic pipeline development helps counterbalance this.

3. Is GSK expanding into emerging markets?
Yes. It invests in low-cost vaccines and partnerships in Asia, Africa, and Latin America to boost growth.

4. How does GSK’s R&D investment compare to peers?
It invests roughly 15% of sales in R&D, on par with leading industry players like Merck and Johnson & Johnson.

5. What are GSK’s future growth drivers?
Pipeline approvals in immunology, oncology, and gene therapy, expansion in emerging markets, and strategic alliances are key.

---

References

[1] GSK Annual Report 2022. (2023). GlaxoSmithKline.
[2] Statista. (2023). Top pharmaceutical companies worldwide by revenue.
[3] EvaluatePharma. (2023). R&D expenditure analysis.
[4] Reuters. (2023). GSK strategic divestments and alliances.